Microdosing means taking a dose low enough that most people can function normally, often without any obvious perceptual change. Macrodosing means taking a dose that reliably produces a full psychedelic experience, one that requires a supervised, session-style setting rather than a normal workday. There is no single milligram line that separates them for every substance or every person, and even “sub-perceptual” microdoses can be noticeable. The safety gap is real: clinical macrodose sessions happen under supervision, while microdosing is almost always unsupervised.
TL;DR:
- Microdosing typically involves doses that preserve normal functioning but can still cause subtle mood or sensory shifts, with effects varying based on individual factors.
- Clinical macrodose protocols use fixed, supervised doses around 25 milligrams of psilocybin, which produce full psychedelic experiences in controlled settings.
- Evidence from controlled trials shows no cognitive enhancement from microdosing and a decrease in cognitive control, challenging its popular focus or productivity claims.
- Risks are higher for individuals with psychiatric or cardiovascular history, especially when combining psychedelics with certain medications like SSRIs, SNRIs, or MAOIs.
- Conversions from dried mushrooms to clinical doses are approximate; a typical 25 mg dose equals roughly 2.5 grams of dried mushroom, but potency varies widely between specimens.
Table of Contents
- How researchers define dosing categories and common ranges
- What clinical trials and surveys actually show
- How the experience and impairment differ by dose
- Who should avoid it and what can go wrong
- A practical checklist for reducing risk at either dose
- Converting clinical doses into approximate mushroom amounts
- Where the research still falls short
- What the evidence actually supports
- The Shroomz Store as a labeled alternative to guesswork
- Sources
- FAQ
How researchers define dosing categories and common ranges
Dose labels in this space are messier than they sound. A milligram figure that counts as a microdose for one person can produce noticeable effects in another, depending on body weight, mushroom potency, gut absorption, and even mood going into the session. That variability is why a growing number of researchers argue for defining doses by their expected effect rather than a fixed number.
The clearest version of this argument comes from a 2026 discussion of dosing terminology, which proposes an effect-based lexicon: microdose, minidose, and macrodose, with ranges that shift depending on the substance and the person. The piece argues that point estimates cause confusion, and that categories should be built around expected subjective effects and functional impairment rather than a single milligram cutoff, as described in the dosing lexicon debate. Under this framework, a microdose is a dose expected to preserve normal functioning. A minidose sits in a gray zone with mild but manageable effects, and a macrodose is expected to produce a full psychedelic experience that interferes with ordinary tasks.
Even so, researchers need numbers to design studies, and a few conventions show up repeatedly in the literature:
- Psilocybin microdoses in controlled research have ranged roughly within a small fraction of a gram of dried mushroom equivalent, according to the dose ranges used across studies in a recent meta-analysis.
- Clinical macrodose protocols commonly use a fixed 25 mg psilocybin dose, validated against earlier weight-based dosing roughly around a third of a milligram per kilogram, per therapeutic dosing guidance.
- LSD microdoses in the same meta-analysis ranged from low single-digit to low tens of micrograms, a fraction of a typical recreational or clinical dose.
- The rough community convention of a microdose being about 10% of a full dose lines up reasonably well with these clinical numbers, though it is a heuristic, not a pharmacological rule.
Dried mushroom potency varies enormously between species, growing conditions, and even different mushrooms from the same batch, which is one reason conversions from milligrams to grams are always approximate rather than exact. Anyone weighing out doses from whole mushrooms is working with an estimate, not a lab-verified number, a point covered in more detail in a comparison of microdosing and macrodosing approaches.
What clinical trials and surveys actually show
Three different kinds of evidence get cited in microdosing and macrodosing discussions, and they answer different questions. Controlled trials test whether an effect holds up against a placebo. Clinical macrodose protocols test therapeutic outcomes under strict supervision. Large surveys capture what people report about their own experiences, without any control group at all.
The most rigorous recent look at microdosing comes from a 2025 preregistered meta-analysis pooling 14 controlled studies with 1,614 participants total. It found no detectable general cognitive benefit from psychedelic microdosing, and it identified a statistically significant decrease in cognitive control, the mental function involved in filtering distractions and switching between tasks, according to the systematic review and meta-analysis. The dose ranges across those 14 studies included roughly 0.1 to 0.5 grams of psilocybin and 6.5 to 20 micrograms of LSD, the same ranges cited above.
A 2025 meta-analysis of 1,614 participants across 14 controlled trials found no broad cognitive enhancement from microdosing and a measurable drop in cognitive control, according to the pooled analysis, a finding that cuts against much of the popular narrative around microdosing for focus or productivity.
Macrodose research tells a different story, but only inside a specific context. Clinical trials using fixed 25 mg psilocybin doses, delivered in screened, supervised sessions with trained monitors present, have shown effects in certain indications, and protocol design (screening, preparation, the session itself, and structured follow-up) is treated as part of the treatment, not an afterthought, per dosing and administration guidance. That context matters enormously: a supervised 25 mg session in a clinical trial is not the same intervention as an unsupervised high dose taken alone at home, even though the milligram number might match.
Large surveys sit in between these two evidence types. They show that microdosing is a widespread pattern of use, but they cannot separate a real pharmacological effect from expectancy, that is, people feeling better partly because they expect to feel better. A 2022 population survey of chronic pain sufferers found that both microdoses and macrodoses were associated with perceived pain relief, though macrodoses produced larger and longer-lasting reported relief, according to the analgesic potential survey. Self-report data like this is useful for generating hypotheses, but it cannot substitute for the placebo-controlled design used in the meta-analysis above. A closer look at what the trial evidence does and does not support for one common use case is covered in a review of microdosing for anxiety.
- Meta-analyses offer strong evidence because they pool controlled, placebo-compared studies, though their quality is limited by the trials included.
- Fixed-dose clinical trials show what a macrodose can do under ideal, supervised conditions, but their findings do not automatically transfer to unsupervised settings.
- Population surveys capture real-world patterns of use and self-reported outcomes, but expectancy and selection bias likely inflate the benefits people report.
How the experience and impairment differ by dose
A microdose is designed to sit below the threshold of a full psychedelic experience, but “sub-perceptual” is not the same as “undetectable.” People taking microdoses commonly report subtle shifts in mood, energy, or sensory sharpness, and the meta-analysis above found a real, measurable effect on cognitive control, meaning microdoses are not simply inert placebos even when they feel unremarkable.
A macrodose is a different category of experience entirely. Clinical protocols describe altered perception, shifts in the sense of self, and emotional intensity strong enough that trained monitors stay present throughout the session, consistent with the screening and monitoring standards described in FDA draft guidance for psychedelic clinical trials. That level of intensity is exactly why macrodosing calls for a controlled setting rather than a normal day at work or behind the wheel.
- Typical microdose reports include mild mood lift, subtle changes in focus, and sometimes minimal perceptual effects, alongside evidence of decreased cognitive control in controlled testing.
- Typical macrodose reports include pronounced perceptual changes, altered perception of time, and emotional intensity that necessitates a supervised, safe environment.
- Functional impairment under a macrodose prevents activities like driving, operating machinery, or making critical decisions during the session; microdosing may involve smaller but still present attention and cognitive risks.
- Tolerance to psilocybin and LSD can develop rapidly with repeated use over several days, reducing effects if dosing is too frequent.
That rapid tolerance pattern is part of why most microdosing schedules use spaced-out cadences rather than daily use, and it is a factor clinical macrodose protocols sidestep entirely by limiting sessions to widely spaced, single events rather than a repeated routine.
Pro Tip: Treat any macrodose session like a clinical one, even outside a trial: no work commitments, no driving, and someone else present who is not dosing.
Who should avoid it and what can go wrong
Certain groups face meaningfully higher risk from either dose category, and the risk is not evenly distributed across the population. People with a personal or family history of psychosis or bipolar disorder are commonly advised against psychedelic use of any kind, since classic psychedelics can trigger or worsen psychiatric symptoms in vulnerable individuals, a caution echoed in NCCIH guidance on psilocybin. People with unstable cardiovascular disease also face added risk, since psychedelics can raise heart rate and blood pressure during the acute effects window.
Medication interactions add another layer of risk that is often overlooked. SSRIs and SNRIs can blunt the subjective effects of psilocybin and LSD in some people, which sometimes leads to dose escalation and a false sense that a low dose is safe to increase. MAOIs pose a more serious concern: combining them with classic psychedelics can cause unpredictable and intense reactions, which is why clinical trial screening protocols specifically ask about current medications before enrollment, consistent with the screening emphasis in FDA draft guidance on psychedelic trials. A closer breakdown of these risk categories and screening questions is available in a dedicated risk overview.
- Avoid or seek medical guidance first if there is a personal or family history of psychosis, bipolar disorder, or cardiovascular instability.
- Flag current medications, especially SSRIs, SNRIs, and MAOIs, since these interact with psilocybin and LSD in ways that change intensity or risk.
- Watch for acute danger signs: severe agitation, signs of psychosis, chest pain, or seizures all warrant emergency medical attention, not waiting it out.
- Screening, preparation, supervision, and follow-up are the four pillars that make clinical trial macrodosing safer than an equivalent dose taken alone.
Clinical trial guidance treats screening and monitoring as critical safety factors, with follow-up assessments extending at least 12 weeks, according to FDA draft guidance, highlighting that safety depends on the full clinical context, not just dose.
A practical checklist for reducing risk at either dose
Whether someone is researching microdosing or considering a supervised macrodose experience, the same basic risk-reduction logic applies before, during, and after.
- Screen yourself honestly first: note any psychiatric history, current medications, and cardiovascular risk factors before considering any dose.
- Set and setting matter most for macrodoses: a calm, familiar space, a sober person present, and zero obligations for the rest of the day are the baseline for any full-dose session.
- Keep microdosing routines conservative: space doses out rather than taking them daily, since tolerance builds quickly and daily unsupervised dosing adds uncertainty without added benefit.
- Track how you respond before assuming a given amount is your baseline, since potency varies batch to batch even within the same product line, a variability explained in more detail in a guide to calculating mg per piece in mushroom chocolate.
- Know the emergency signs: severe agitation, chest pain, seizures, or signs of psychosis call for urgent medical care, not a wait-and-see approach.
Pro Tip: If a macrodose session is being considered for a specific mental health condition, a supervised clinical trial or licensed provider is a materially different (and safer) context than an unsupervised session at home.
Converting clinical doses into approximate mushroom amounts
Clinical psilocybin doses are reported in milligrams of pure psilocybin, but most people encounter mushrooms as dried plant material, which makes conversion necessary and imprecise at the same time. Dried Psilocybe cubensis is commonly estimated at around 1% psilocybin content by weight, with a variability range of roughly 0.5% to 2% depending on the specimen, according to therapeutic dosing guidance.
| Dose category | Psilocybin amount | Approximate dried mushroom equivalent |
|---|---|---|
| Microdose | 2.5 to 5 mg | 0.1 to 0.5 g |
| Minidose | 5 to 10 mg | 0.5 g |
| Clinical macrodose | 25 mg | approximately 2.5 g |
These figures are estimates built on an average potency assumption, not a guarantee for any specific batch: two mushrooms from the same grow can differ in potency by a meaningful margin, which is exactly why product potency and species variability make retail conversions approximate rather than precise. Readers working with edible formats instead of raw mushrooms can find format-specific onset and dosing detail in a guide to gummy onset timing.
Where the research still falls short
The biggest weakness in microdosing research is blinding. Participants in controlled trials often correctly guess whether they received a microdose or a placebo, which means part of any reported benefit could come from expectation rather than pharmacology, an issue that runs through much of the underlying literature feeding into the 2025 meta-analysis.
Beyond blinding, most microdosing studies share a handful of limitations: small sample sizes, inconsistent dosing protocols between studies, and short follow-up periods that cannot speak to what happens with months or years of repeated use.
- Blinding failures undermine confidence that reported microdose effects are pharmacological rather than expectancy-driven.
- Small, heterogeneous trials make it hard to compare results across studies that used different doses, schedules, and outcome measures.
- Short follow-up windows leave long-term safety, including cumulative effects of repeated low-dose exposure, largely unanswered.
- Standardized potency reporting, longer safety studies, and better placebo controls are the clearest priorities for closing these gaps.
What the evidence actually supports
The honest read of the current evidence is that macrodosing has real, if still developing, clinical promise, and microdosing does not have much to stand on yet. A 25 mg supervised psilocybin session inside a screened clinical trial is a genuinely different intervention from a home microdose taken before a work meeting, and conflating the two does the topic a disservice.
If you are drawn to a macrodose experience for a specific mental health condition, a supervised clinical trial or licensed provider is the appropriate starting point, not a solo session. If you are curious about microdosing, treat the current evidence as inconclusive at best, and skip it entirely if you have a personal or family history of psychosis or bipolar disorder. For deeper, vetted reading beyond this article, primary sources like peer-reviewed meta-analyses and government guidance documents are worth more than forum anecdotes.
— Jake
The Shroomz Store as a labeled alternative to guesswork
Part of what makes dosing conversions frustrating is that raw mushrooms rarely come with a reliable potency label. The marketplace sells a variety of mushroom-derived products, including edibles, gummies, chocolate, capsules, and raw mushrooms, with some products designed to offer a consistent amount per serving rather than relying on potency estimates.
None of this replaces a clinician for a clinical use case: The Shroomz Store is an information-forward marketplace, not a medical provider, and its educational library exists to help people understand mushroom products, not to substitute for a psychiatric evaluation or supervised care.
- Edibles and gummies offer a labeled dose per piece, useful for anyone trying to avoid the guesswork of weighing dried mushrooms.
- Capsules provide a fixed amount per capsule for a more measured, repeatable routine.
- Raw mushrooms remain available for readers who prefer to weigh their own doses using the conversion estimates above.
Anyone weighing microdosing against a supervised macrodose experience can browse capsules or the full edibles category for a labeled starting point, or consult a clinician first when a specific mental health condition is the reason for considering a macrodose at all.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis
- Therapeutic use of psilocybin: Practical considerations for dosing and administration
- FDA issues first draft guidance: clinical trials of psychedelic drugs
- How small is a microdose, how big is a macrodose?
FAQ
Is there an official milligram cutoff between a microdose and macrodose?
No, there is no universally accepted numeric boundary, since effects depend on the substance, body weight, and individual sensitivity. Researchers increasingly define these categories by expected subjective effect and functional impairment rather than a single number, as argued in the dosing lexicon discussion.
Does microdosing actually improve focus or mood?
Controlled evidence does not support a general cognitive benefit. A 2025 meta-analysis of 1,614 participants across 14 controlled studies found no broad cognitive enhancement and identified a measurable decrease in cognitive control, according to the pooled meta-analysis.
How much dried mushroom equals a clinical 25 mg psilocybin dose?
Using a common potency estimate of about 1% psilocybin per gram of dried Psilocybe cubensis, a 25 mg clinical dose works out to roughly 2.5 grams, according to therapeutic dosing guidance.
Who should avoid microdosing or macrodosing entirely?
People with a personal or family history of psychosis or bipolar disorder, and those with unstable cardiovascular disease, face higher risk from classic psychedelics at either dose level, per NCCIH guidance. Anyone taking SSRIs, SNRIs, or MAOIs should also get medical guidance first, since these medications interact with psilocybin and LSD in ways that change effects or risk.
Are macrodose clinical trials safe to replicate at home?
Not reliably, because trial safety depends on screening, preparation, in-session supervision, and structured follow-up, not the dose alone. FDA draft guidance for psychedelic drug trials treats these surrounding conditions as core safety variables, which is exactly what an unsupervised session at home lacks.
